In vitro Activities of Polycalcium, a Mixture of Polycan and Calcium Lactate-Gluconate, on Osteoclasts and Osteoblasts

Choi, Jae‐Suk; Kim, Joowan; Kim, Ki‐Young; Cho, Hyung-Rae; Ha, Yu-Mi; Ku, Sae Kwang; Cho, Kwang Keun; Choi, Inhee

doi:10.5352/jls.2011.21.8.1199

Cited by 5 publications

(5 citation statements)

References 16 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The synergistic effects of Polycan and other materials containing calcium on osteoporosis have been previously demonstrated. Polycan and calcium lactate–gluconate (1:9, w/w) were shown to have synergistic antiosteoporotic effects in vitro [19]. In addition, a dose of 400 mg Polycan and calcium lactate–gluconate (1:9, w/w) has been proven to improve bone metabolism and was well tolerated and safe in a 4-week open-label clinical study [27].…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have reported a synergistic effect of glucosamine and other compounds, such as chondroitin, on knee osteoarthritis [6, 17, 18]. In vitro studies have demonstrated a synergistic effect of a Polycan and calcium lactate–gluconate mixture on osteoclast and osteoblast activity [19], and similar effects have been demonstrated in rats with surgery-induced osteoarthritis [14]. However, a synergistic effect of glucosamine and Polycan on knee osteoarthritis has not been confirmed.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Double-Blind, Randomized Controlled 12-Week Follow-Up Trial to Evaluate the Efficacy and Safety of Polycan in Combination with Glucosamine for the Treatment of Knee Osteoarthritis

Truong¹,

Lim²,

Cho³

et al. 2019

Evidence-Based Complementary and Alternative Medicine

Self Cite

View full text Add to dashboard Cite

Aim. The aim of the present study was to examine the efficacy and safety of Polycan, a β-glucan produced from the black yeast Aureobasidium pullulans SM-2001, in combination with glucosamine in reducing knee osteoarthritis-associated symptoms. Methods. This was a double-blind, randomized controlled trial of a formulated product composed of 16.7 mg of Polycan and 250 mg of glucosamine (Group A), 16.7 mg of Polycan and 500 mg of glucosamine (Group B), or 500 mg of glucosamine (control group) per capsule, administered as three capsules once per day over a period of 12 weeks, conducted with 100 osteoarthritis patients, aged 35–80 years. The primary outcome measure was osteoarthritis symptoms assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire. The secondary outcome measures included rescue medication use (according to data from a patient-reported diary) and other safety indices (body weight, blood pressure, hematological, and biochemistry markers). Results. Compared with the control group, Group B demonstrated a statistically significant reduction in the total WOMAC score after 12 weeks of treatment (p < 0.05). There was a significant reduction in the frequency of rescue medication used in Groups A and B compared with the control group (p < 0.05). There were no significant changes in hematology and biochemistry parameters or health indices between the active and the control group. Conclusion. Among patients with mild or moderate osteoarthritis, a daily oral dose of Polycan (50 mg) in combination with glucosamine (750 mg or 1500 mg; Group A or B, respectively) resulted in a better treatment outcome than treatment with glucosamine (1500 mg) alone.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Double-Blind, Randomized Controlled 12-Week Follow-Up Trial to Evaluate the Efficacy and Safety of Polycan in Combination with Glucosamine for the Treatment of Knee Osteoarthritis

Truong¹,

Lim²,

Cho³

et al. 2019

Evidence-Based Complementary and Alternative Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previously, we investigated the effects of a mixture of polycan and calcium lactate gluconate (polycalcium) on osteoporosis in murine osteoclast progenitor cells (RAW264.7) [ 177 ]. Osteoblast proliferation was stimulated, which prevented RANKL-induced osteoclast differentiation of RAW264.7 cells.…”

Section: Bone Regeneration/bone Injury Healing Effects Of β-Glucanmentioning

confidence: 99%

“…Previously, we reported on the significant antiosteoporotic effects of polycalcium in in vitro and animal-based studies [ 177 , 178 , 181 , 182 ]. We also estimated the antiosteoporotic effects of polycalcium in human-based clinical trials [ 185 ].…”

Section: Bone Regeneration/bone Injury Healing Effects Of β-Glucanmentioning

confidence: 99%

Clinical and Physiological Perspectives of β-Glucans: The Past, Present, and Future

Bashir

Choi

2017

IJMS

Self Cite

182

107

View full text Add to dashboard Cite

β-Glucans are a group of biologically-active fibers or polysaccharides from natural sources with proven medical significance. β-Glucans are known to have antitumor, anti-inflammatory, anti-obesity, anti-allergic, anti-osteoporotic, and immunomodulating activities. β-Glucans are natural bioactive compounds and can be taken orally, as a food supplement, or as part of a daily diet, and are considered safe to use. The medical significance and efficiency of β-glucans are confirmed in vitro, as well as using animal- and human-based clinical studies. However, systematic study on the clinical and physiological significance of β-glucans is scarce. In this review, we not only discuss the clinical and physiological importance of β-glucans, we also compare their biological activities through the existing in vitro and animal-based in vivo studies. This review provides extensive data on the clinical study of β-glucans.

show abstract

“…14,15 Polycalcium, a mixed formula consisting of water-soluble Ca salts and Polycan, is regarded as an alternative agent, improving solubility and chelate formation, compared with previous Ca supplements. Additionally, Polycalcium was shown to have synergistic antiosteoporotic effects in vitro, 16 and Polycan was shown to have an antiosteoporotic effect in vivo, 11 demonstrating its potential as a new preventative or therapeutic agent against osteoporosis. However, to our knowledge, there has been no report about whether it has synergistic antiosteoporotic effects in healthy perimenopausal women.…”

mentioning

confidence: 99%

Safety and Efficacy of Polycalcium for Improving Biomarkers of Bone Metabolism: A 4-Week Open-Label Clinical Study

Choi

Park

Kim

et al. 2013

Journal of Medicinal Food

Self Cite

View full text Add to dashboard Cite

Polycalcium is a mixture of Polycan and calcium lactate-gluconate 1:9 (w/w) with demonstrated antiosteoporosis activity in vitro and in vivo studies. These studies were a 4-week open-label, single-center trial to evaluate the efficacy of oral Polycalcium on bone metabolism and safety. In total, 30 healthy women (range 40-60 years) were administered 400 mg of Polycalcium for 4 weeks. The primary efficacy parameter was urinary deoxypyridinoline (DPYR) levels, and serum osteocalcin (OSC), bone-specific alkaline phosphatase (BALP), urinary cross-linked C-telopeptide of type-1 collagen (CTx), urinary cross-linked N-telopeptide of type-1 collagen (NTx), calcium (Ca), and phosphorus (P) levels, which were evaluated for comparison before and after administration of Polycalcium. After 4 weeks of Polycalcium administration, 27 subjects completed the test plan. Three subjects withdrew their consent to participate. The values of blood OSC, BALP, serum Ca, and serum P from baseline to 4 weeks of treatment were changed by -28.44%, 14.37%, 6.11%, and 1.42%, respectively. Biomarkers of bone resorption: urinary DPYR, serum CTx, serum NTx, urinary Ca, and urinary P, at baseline after 4 weeks of treatment were changed by -13.40%, 6.67%, -5.13%, -22.43%, and -3.04%, respectively. Additionally, when considering the subjects' adverse effects and the results of the blood and urine tests over the 4-week trial period, the dose of 400 mg Polycalcium showed efficacy for improving bone metabolism and was well tolerated and safe. Polycalcium was apparently safe and efficacious.KEY WORDS: b-glucans bone turnover calcium human application test Polycalcium O steoporosis is a metabolic bone disease that results from a disturbance in normal bone remodeling, tilting the balance to bone resorption over formation. There is an imbalance between bone resorption and formation, resulting in bone loss and fractures after mineral flux.

show abstract

In vitro Activities of Polycalcium, a Mixture of Polycan and Calcium Lactate-Gluconate, on Osteoclasts and Osteoblasts

Cited by 5 publications

References 16 publications

A Double-Blind, Randomized Controlled 12-Week Follow-Up Trial to Evaluate the Efficacy and Safety of Polycan in Combination with Glucosamine for the Treatment of Knee Osteoarthritis

A Double-Blind, Randomized Controlled 12-Week Follow-Up Trial to Evaluate the Efficacy and Safety of Polycan in Combination with Glucosamine for the Treatment of Knee Osteoarthritis

Clinical and Physiological Perspectives of β-Glucans: The Past, Present, and Future

Safety and Efficacy of Polycalcium for Improving Biomarkers of Bone Metabolism: A 4-Week Open-Label Clinical Study

Contact Info

Product

Resources

About